Traduction de «costs research and development » (Anglais → Français) :

(9) With a view to encouraging the dissemination of research results, SMEs may receive aid for the costs of obtaining and validating patents and other industrial property rights resulting from research and development activities.

To conclude, there must be support for modernization of traditional economic sectors, support for industrial research and research and development, measures enabling industries to exploit their capabilities in a highly competitive context, measures that will offset increased oil costs with the development of clean and renewable energy.

Estonia was therefore invited to take part in the next meeting of the COST Committee of Senior Officials on 17 and 18 October 1996 to present its RD policy. In the context of COST decisions to authorize RD institutes in non-COST countries to participate in individual actions, the Committee approved participation as follows: - Romania: Romanian Transport Research Institute Participation in COST Action 330: Teleinformatics links between ports and their partners - Hong Kong: Chinese University of Hong Kong Participation in COST A ...[+++]ction B3: Development of new radiotracers and methods of quality assurance for nuclear medicine application - Cyprus: Ministry of Agriculture, Natural Resources and the Environment Participation in COST Actions 66 and 67: -COST 66: Pesticides, Soil and Environment -COST 67: Chemodynamics and water quality protection in natural porous media - Cyprus: University of Cyprus (Department of Computer Science) Participation in COST Action 15: Many-valued Logics for Computer Science Applications - Russia: Institute of Applied Geophysics (Moscow) Participation in COST Action 251: Improved quality of service in ionospheric telecommunications systems planning and operation The Committee gave its approval to the extension of the following Actions: - COST 241: Characterization of advanced fibres for the photonic network (for 18 months) - COST 321: Research in the field of urban goods transport (for one year) The Committee approved the following new Actions: - COST 335: Passenger accessibility of heavy rail systems - COST 917: Biogenically active amines in food - COST 244bis: Biomedical Effects of Electro-magnetic Fields - COST 219bis: Access for elderly and disabled people to the information society - COST G3: Industrial ventilation The last two Actions will be given final approval by means of the written procedure.

The salient features of the arrangements to be rolled over are the following: - maximum aid rate 40% of eligible product development costs as defined in Annex II to the Community framework for aid to research and development ( OJ C 83/1986) - ( exception: 50% for projects involved with the development of organic products as defined in Regulation 2092/91 or where the value of the applicant's own work (ineligible for aid under this s ...[+++]cheme) represents a substantial part of project costs); - 100% of the aid must be reimbursed upon any commercial exploitation of the results of the development work; - the scheme is primarily aimed at SMEs as defined in the Community framework for aid to SMEs ( OJ C213/1992 ) - any aid planned for non- SMEs is to be notified on a case-by-case basis; The total budget proposed for the scheme is: 1994 1995/6/7 183 m DKR 210 m DKR per annum (appr 25 MECU) (appr 28 MECU) It is to be noted that, as in the case of the existing aid, these figures for the overall budget include estimated revenue from aid reimbursed under the "commercial exploitation" rule outlined above and subsequently ploughed back into the scheme.

COUNCIL RESOLUTION DESIGNED TO IMPLEMENT THE OUTLINES OF AN INDUSTRIAL POLICY IN THE PHARMACEUTICAL SECTOR IN THE EUROPEAN UNION THE COUNCIL Having regard to the Commission communication of 14 September 1994 entitled "An industrial competitiveness policy for the European Union"; Recalling its Resolution of 21 November 1994 on strengthening the competitiveness of Community industry [10] , and its conclusions of 7 April 1995 on an industrial competitiveness policy; Having regard to the communication of 2 March 1994 from the Commission to the Council and the European Parliament on the outlines of an industrial policy for the pharmaceutical sector in the European Union; Whereas the European Union has an important role to play in creating a f ...[+++]avourable environment for the expansion of activities relating to research, development, production and distribution of medicinal products and in encouraging the development of an innovative and effective European pharmaceutical industry in terms of competitiveness on the world market; Whereas European industrial policy must necessarily take account of the special nature of this sector, which relates both to public health and to social policy; whereas social security systems bear a considerable proportion of pharmaceutical expenditure; whereas this is a matter which falls within the competence of the Member States; Whereas the European Union has the responsibility of sketching out guidelines for the promotion of Community activities in this sector, HAS ADOPTED THIS RESOLUTION: I. WITH RESPECT TO THE SITUATION IN THE PHARMACEUTICAL INDUSTRY 1. recalls that the European pharmaceutical industry plays an essential role in public health, remains a high-technology industry with considerable added value, which is particularly successful, generates highly skilled jobs and makes a significant contribution to the Union's balance of trade; 2. considers that, now that it is facing increasingly intense international competition, the Euro ...

For repairs such investment must be linked to a restructuring plan resulting in an overall reduction of the country's ship repair capacity. b) 30 % of the closure if it is considered irreversible under Article 7(1) of the Seventh Directive. c) 30 % of eligible costs for basic research and basic industrial research and 25 % for applied research and development in conformity with the Community framework for state aids for research ...[+++] and development (OJ C 83, 11.04.1986).